Doug Godfrin, PhD - VeraMorph

Why Sal Is Bullish on Biotech VeraMorph has a new way to deliver insoluble drugs by mouth. Founder Doug Godfrin, PhD elucidates the promise of accessing the 85% of drugs that are not soluble. Does VeraMorph pass Sal Daher's screen for angel-scale biotech? Listen and find out. Sponsors: Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson Highlights: Sal Daher, CFA Introduces Doug Godfrin, PhD, Founder of VeraMorph A New Way to Deliver Drugs Orally How VeraMorph Gets Around the Solubility Problem VeraMorph's Approach Is Janus-like: Shelf Stable but Available Where Needed The Decade of Biotech & VeraMorph AltrixBio: Gastric Bypass Surgery in a Pill Sal Daher's Biotech Screen: Strong Patents "VeraMorph actually owns the patents outright for this platform technology." "We've really taken a totally different perspective with this class of material by focusing on immediate release via oral delivery..." Sal Daher's Biotech Screen: Capable Academic Founder Sal Daher's Biotech Screen: Is it Angel-Scale? US$1 Million Will Get VeraMorph to Production for Pre-Clinical Trials "...chances of reaching that next set of milestones is 90% or above." Doug Godfrin Is Collaborating with Colin Minchom, PhD, a Veteran of Drug Development US$ 2 to 3 million More Will Take VeraMorph to Clinical Stage, Doug Predicts Sal and Doug Look at the Odds of Getting to Clinical Stage Sal Daher's Biotech Screen: Do Strategics Care? Sal Daher's Biotech Screen: Platform Technology? Sponsors Purdue University and Peter Fasse Are Founder-Friendly The Upside of Failure in Biotech This guy calls me up, "Saleh, let's get together at Darwin's in Cambridge. I want to talk to you about a new company." Doug Godfrin's Parting Thoughts Topics: biotech